Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817778 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00817778 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 27 participants.
The verdict
NCT00817778, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin
Interventions
- DRUG Placebo
- DRUG AZD1656
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817778
The ClinicalTrials.gov registry entry for NCT00817778 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00817778 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00817778 about?
NCT00817778 is a clinical study titled "Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin". The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin
What is the current status of trial NCT00817778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-01. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00817778?
The interventions under investigation include: Placebo (DRUG), AZD1656 (DRUG).
Who is sponsoring clinical trial NCT00817778?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.